Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
United Drug shares were up 1.35% to 284.80p at 08:49 on Tuesday.
Group revenues and profits for the three months to December 31st will be ahead of the same period last year at United Drug, the company has forecast. In an interim management statement issued on Tuesday, the healthcare provider reported that trading across the group had been "strong" over the quarter, with much of the growth it experienced coming from international operations with the businesses outside of Ireland contributing to in excess of 70% of group profits. During the fiscal year, the group announced five acquisitions. Four of the five businesses acquired have now been fully integrated. Final competition clearance for the fifth - the acquisition of Pharmexx - was received in November and has since been completed. Since then, the group reported that it had been implementing a detailed integration plan to standardise processes and procedures in the acquired business. Based on its trading performance for the year to date, United Drug reported that it expected constant currency adjusted diluted earnings per share for the year to September 30th, before non-recurring costs associated with acquisition activity and restructuring, to be betweebn 5.0% and 8.0% ahead of last year.
United Drugs: Jefferies raises target price from 260p to 310p and keeps a buy recommendation.
United Drug: Investec initiates with a target price of 240p and a sell recommendation.
Brought this stock about a year ago on a recommendation and had been thinking for the last year that I had made a mistake. Its racing away now and still some way to go IMO...
United Drug, a provider of services to healthcare manufacturers and pharmaceutical retailers, has agreed to acquire the entire issued share capital of Synopia, which provides market access services to pharmaceutical and biotech manufacturers in the US market. The purchase, which will be made for a total consideration of up to $12m, is being made to enable to the firm to broaden its range of services to clients in its Sales, Marketing & Medical division. $3.2m of the consideration is payable in cash on completion, with an additional amount of up to $8.8m payable after three years on achievement of agreed profit targets. United Drug also announced plans to acquire the entire issued share capital of Drug Safety Alliance for a total consideration of up to $28m. The firm, which employs 94 people, provides safety and risk management services supporting pharmaceutical, biotech, medical device, animal and consumer health organisations. The business will also form part of United's Sales, Marketing & Medical division and is being purchased to allow United to offer clients an integrated call centre and case processing pharmacovigilance service. $21m of the consideration is payable in cash on completion with an additional amount of up to $7m payable after three years based on achievement of agreed profit targets. Both acquisitions will be financed from United Drug's internal resources and existing debt facilities and is expected to be immediately accretive to earning
Sorry folks - including valuation and some commentary about United Drug
Hi folks, Just posted Part V of The Great Irish Share Valuation Project, including valuation and some commentary about TVC holdings: http://wexboy.wordpress.com/2012/02/22/the-great-irish-share-valuation-project-v/ Cheers, Wexboy
Anybody know why the share price on this stock is spiralling?